ClinicalTrials.gg
RecruitingNCT07731087Updated Jul 28, 2026

MSC Secretome Therapy for Cognitive Recovery After Subacute Ischemic Stroke

An interventional study of Umbilical Cord Mesenchymal Stem Cell-Derived Secretome and Standard Stroke Care and Rehabilitation in Ischemic Stroke and Post-Stroke Cognitive Impairment, sponsored by Jumraini Tammasse. Recruiting at 1 site in Indonesia. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Jumraini Tammasse · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Ischemic Stroke with a site in Indonesia — 3 open to participants now, 4 under way, 1 of them phase 3. Ischemic Stroke · Indonesia.

Planned enrollment
6th of 10
70 · median 75
Started
2026
with 2 others
No phase
2 of 10
2 open now
Registered
9th of 10
by date
Lead sponsor
2 of 10
Jumraini Tammasse

Among the 10 studies in Ischemic Stroke with a site in Indonesia, this one is the 6th largest by planned enrollment, is one of 3 that started in 2026, is one of 2 with no phase, and was the 9th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

3 of the 10 studies in Ischemic Stroke with a site in Indonesia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Ischemic Stroke with a site in Indonesia, or all of them as a file.
02

Study summary

Post-stroke cognitive impairment can limit rehabilitation, independence, and quality of life after ischemic stroke. This pilot randomized controlled trial evaluates whether mesenchymal stem cell-derived secretome, given in addition to standard stroke care and rehabilitation, improves cognitive recovery in patients with subacute ischemic stroke. Participants aged 40 to 75 years with ischemic stroke occurring 7 days to 3 months previously and mild-to-moderate cognitive impairment will be randomly assigned in a 1:1 ratio to receive standard care and rehabilitation plus MSC secretome or standard care and rehabilitation without MSC secretome. The primary outcome is the change in the Indonesian version of the Montreal Cognitive Assessment score. Secondary outcomes include quantitative electroencephalography parameters, serum brain-derived neurotrophic factor, serum interleukin-1β, NIHSS, modified Rankin Scale, and adverse events.

Read the detailed description

This study is a pilot, parallel-group, randomized controlled trial with blinded outcome assessment. The study population consists of patients aged 40 to 75 years with clinically and radiologically confirmed subacute ischemic stroke, defined as 7 days to 3 months after stroke onset. Eligible participants must be hemodynamically stable, able to undergo a basic neuropsychological assessment, and have mild-to-moderate cognitive impairment based on the Indonesian version of the Montreal Cognitive Assessment.

Participants will be randomized in a 1:1 ratio using block randomization with allocation concealment. The intervention group will receive standard stroke care and rehabilitation plus umbilical cord mesenchymal stem cell-derived secretome. The control group will receive standard medical treatment and standardized stroke rehabilitation without MSC secretome. Outcome assessors will remain unaware of treatment allocation.

Baseline assessments include demographic and vascular risk factor data, NIHSS, modified Rankin Scale, MoCA-Ina, quantitative electroencephalography, serum brain-derived neurotrophic factor, and serum interleukin-1β. Follow-up assessments will include cognitive, neurological, functional, electrophysiological, biomarker, and safety evaluations at the prespecified study visits.

The primary outcome is the change in MoCA-Ina total score from baseline to week 8. Secondary outcomes include changes in delta-to-alpha ratio, delta-theta-to-alpha-beta ratio, relative alpha power, relative theta power, serum BDNF, serum IL-1β, NIHSS, modified Rankin Scale, and the incidence of adverse events. The primary analysis will follow the intention-to-treat principle, with per-protocol analysis as an additional analysis.

03

Conditions studied

  • Ischemic Stroke
  • Post-Stroke Cognitive Impairment

Browse trials for

Keywords

  • Subacute ischemic stroke
  • Post-stroke cognitive impairment
  • Mesenchymal stem cell secretome
  • MSC secretome
  • Cognitive recovery
  • MoCA-Ina
  • Quantitative electroencephalography
  • qEEG
  • Brain-derived neurotrophic factor
  • BDNF
  • Interleukin-1 beta
  • IL-1β
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 40 to 75 years.
  2. Diagnosis of ischemic stroke confirmed by clinical examination and computed tomography or magnetic resonance imaging.
  3. Stroke onset between 7 days and 3 months before enrollment.
  4. Hemodynamically stable.
  5. Able to undergo a basic neuropsychological assessment.
  6. Mild-to-moderate cognitive impairment based on the Indonesian version of the .
  7. Willing to participate in the study and provide written .

Exclusion criteria

Exclusion Criteria:

  1. Hemorrhagic stroke or mixed ischemic and hemorrhagic stroke.
  2. Severe aphasia, impaired consciousness, or severe sensory deficits that make cognitive assessment invalid.
  3. History of dementia before stroke or a major neurodegenerative disorder.
  4. Active infection, active disease, active , severe renal failure, or severe liver failure.
  5. Uncontrolled epilepsy.
  6. Concurrent participation in another clinical trial.
  7. to any study intervention or study procedure.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    MSC Secretome Plus Standard of Care

    Participants receive standard medical treatment and standardized stroke rehabilitation plus umbilical cord mesenchymal stem cell-derived secretome. The secretome intervention is administered according to the study protocol, with safety monitoring during and after administration.

    Biological: Umbilical Cord Mesenchymal Stem Cell-Derived Secretome · Other: Standard Stroke Care and Rehabilitation

  • Active comparator
    Standard of Care Alone

    Participants receive standard medical treatment and standardized stroke rehabilitation without MSC secretome.

    Other: Standard Stroke Care and Rehabilitation

Interventions

  • BiologicalUmbilical Cord Mesenchymal Stem Cell-Derived Secretome

    Umbilical cord mesenchymal stem cell-derived secretome is administered in addition to standard medical treatment and standardized stroke rehabilitation. The intervention is administered twice, on day 1 and day 8, according to the investigational product protocol. Participants are monitored during and after administration for hypersensitivity reactions, fever, and other adverse events.

    Also known as: USEPro

  • OtherStandard Stroke Care and Rehabilitation

    Participants receive standard medical management for subacute ischemic stroke and standardized stroke rehabilitation according to the treating physician and institutional clinical practice. The same standard care and rehabilitation are provided to both study groups.

06

What researchers measure

Primary outcomes

  1. Change in Montreal Cognitive Assessment-Indonesian Version Total Score

    The MoCA-Ina assesses visuospatial-executive function, naming, attention, language, abstraction, delayed recall, and orientation. The total score ranges from 0 to 30, with higher scores indicating better cognitive performance. The outcome is the change in total MoCA-Ina score from baseline to the final follow-up assessment.

    Time frame: Baseline to week 8

Secondary outcomes

  1. Change in Delta-to-Alpha Ratio on Quantitative Electroencephalography

    The delta-to-alpha ratio is calculated from quantitative electroencephalography spectral power measurements. The outcome is the change in DAR from baseline to week 4 and week 8.

    Time frame: Baseline, week 4, and week 8

  2. Change in Delta-Theta-to-Alpha-Beta Ratio on Quantitative Electroencephalography

    The delta-theta-to-alpha-beta ratio is calculated from quantitative electroencephalography spectral power measurements. The outcome is the change in DTABR from baseline to week 4 and week 8.

    Time frame: Baseline, week 4, and week 8

  3. Change in Relative Alpha Power on Quantitative Electroencephalography

    Relative alpha power is derived from quantitative electroencephalography spectral power analysis. The outcome is the change in relative alpha power from baseline to week 4 and week 8.

    Time frame: Baseline, week 4, and week 8

  4. Change in Relative Theta Power on Quantitative Electroencephalography

    Relative theta power is derived from quantitative electroencephalography spectral power analysis. The outcome is the change in relative theta power from baseline to week 4 and week 8.

    Time frame: Baseline, week 4, and week 8

  5. Change in Serum Brain-Derived Neurotrophic Factor Concentration

    Serum brain-derived neurotrophic factor concentration is measured using an enzyme-linked immunosorbent assay. The outcome is the change in serum BDNF concentration from baseline to week 8.

    Time frame: Baseline and week 8

  6. Change in Serum Interleukin-1 Beta Concentration

    Serum interleukin-1 beta concentration is measured using an enzyme-linked immunosorbent assay. The outcome is the change in serum IL-1 beta concentration from baseline to week 8.

    Time frame: Baseline and week 8

  7. Change in National Institutes of Health Stroke Scale Score

    The National Institutes of Health Stroke Scale assesses neurological impairment. Scores range from 0 to 42, with higher scores indicating greater neurological impairment. The outcome is the change in NIHSS score from baseline to week 4 and week 8.

    Time frame: Baseline, week 4, and week 8

  8. Change in Modified Rankin Scale Score

    The modified Rankin Scale assesses global disability after stroke. Scores range from 0 to 6, with higher scores indicating greater disability or death. The outcome is the change in modified Rankin Scale score from baseline to week 4 and week 8.

    Time frame: Baseline, week 4, and week 8

  9. Incidence of Treatment-Emergent Adverse Events

    The number and proportion of participants experiencing adverse events, including hypersensitivity reactions, fever, administration-related reactions, hospitalization, seizure, infection, neurological deterioration, and death, will be recorded.

    Time frame: From the first intervention through week 8

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data sharing is not currently planned. Participant data will be coded, stored securely, and reported only in aggregate form without direct personal identifiers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Nov 2026, 4 months after the start.

Of 573 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 4 months is below that.

Counting every sponsor, half of 654 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2026
First posted
Jul 28, 2026
StartActual
Jul 9, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07731087
Lead sponsor
Jumraini Tammasse
Responsible party
Jumraini Tammasse (Principal Investigator, Hasanuddin University) — Sponsor-investigator
First posted
Jul 28, 2026
Start date
Jul 9, 2026
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 28, 2026

Study contacts

Jumraini Tammasse, Sp.N, Subsp.NRE(K)
Contact
tejayanovi@gmail.com
+6282188833368
Jumraini Tammasse, Sp.N, Subsp.NRE(K)
principal investigator · Hasanuddin University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion